ViGenCell Inc is a Korea-based company principally engaged in the development of cell therapy business. The Company is engaged in the development and manufacture of immuno-cancer cell therapy products and immunosuppressive cell therapy products. In addition, the Company is engaged in the provision of vitier platform as an antigen-specific killing t cell treatment, viranger platform as a gammadelta t cell gene therapy and vimedier platform-based technology as a myeloid suppressor cell therapy derived from umbilical cord blood. It is engaged in the research and development of new drugs such as acute myeloid leukemia (AML) and glioblastoma.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-05	₩5,350.00	+0.38%	101,185
26-08-05	₩5,330.00	+3.70%	96,042
26-08-04	₩5,140.00	+5.87%	108,821
26-08-03	₩4,855.00	+1.78%	90,377
26-07-31	₩4,770.00	+7.67%	102,731

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2026-08-06			5-day change	1st Jan Change
5,350.00 ^KRW	+0.38%		+17.45%	-45.13%

25-01-22	Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. from Boryung Corporation.	CI
24-12-17	Gaeun Global Co.,Ltd agreed to acquire 11.36% stake in ViGenCell Inc. from Boryung Corporation for KRW 7.9 billion.	CI

Market Cap	200B 141M 122M 114M 104M 197M 13.39B 200M 1.34B 524M 6.69B 528M 516M 22.26B	P/E 2023	-6.24x	P/E 2024	-3.42x
Enterprise Value	162B 114M 99.1M 92.8M 84.89M 160M 10.88B 162M 1.09B 426M 5.44B 429M 419M 18.09B	EV / Sales 2023	-	EV / Sales 2024	38,429,949x
Free-Float	73.84%	Yield 2023 *	-	Yield 2024	-

25-01-22	Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. from Boryung Corporation.	CI
24-12-17	Gaeun Global Co.,Ltd agreed to acquire 11.36% stake in ViGenCell Inc. from Boryung Corporation for KRW 7.9 billion.	CI
23-09-18	ViGenCell Inc.(KOSDAQ:A308080) dropped from S&P Global BMI Index	CI
23-03-15	ViGenCell Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-03-21	ViGenCell Inc.(KOSDAQ:A308080) added to S&P Global BMI Index	CI

1 day	+0.38%
1 week	+17.45%
Current month	+12.16%
1 month	-5.81%
3 months	-48.21%
6 months	-33.71%
Current year	-45.13%

ViGenCell Inc. Stock

Stocks

A308080

KR7308080001

Biotechnology & Medical Research

Valuation: ViGenCell Inc.

Chart: ViGenCell Inc.

Latest news : ViGenCell Inc.

Quotes and Performance

Course Extremes

Managers and Directors: ViGenCell Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4,475	5,600
1 month	4,320	6,690
Current year	4,320	14,400
1 year	3,070	17,360
3 years	2,305	17,360
5 years	2,305	39,000
10 years	2,305	39,000

Manager	Title	Age	Since
Pyung-suk Ki CEO	Chief Executive Officer	-	-
Tae Gyu Kim CEO	Chief Executive Officer	68	-
Hyun-Jung Son PRN	Corporate Officer/Principal	53	-

Director	Title	Age	Since
Tae Gyu Kim BRD	Director/Board Member	68	-
Kyung-Muk Kim BRD	Director/Board Member	57	-
Hyun-Jung Son BRD	Director/Board Member	53	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/30/24	Seong-Jong Kim	Fiscal year		35,000	0.1826%
4/30/24	Kyung-Muk Kim	Fiscal year	Director	63,000	0.3287%
4/30/24	Seong-Jong Kim	Don		40,440	0.2110%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIGENCELL INC.	+0.38%	+17.45%	+50.28%	-13.71%	76.78M
WUXI APPTEC CO., LTD.	-3.25%	+12.81%	+52.96%	+88.86%	64.9B
ARGENX SE	+0.69%	-2.81%	+25.84%	+68.41%	54.05B
BIONTECH SE	-1.07%	-1.79%	-18.07%	-7.42%	23.16B
INSMED INCORPORATED	+33.86%	+30.60%	+19.14%	+506.08%	21.46B
WUXI BIOLOGICS (CAYMAN) INC.	+1.87%	+5.08%	+29.88%	-7.94%	21.25B
GENMAB A/S	-0.79%	+0.54%	+31.17%	-25.84%	17.94B
PHARMAESSENTIA CORPORATION	-3.37%	+19.44%	+211.98%	+369.13%	17.03B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.29%	+2.09%	+17.32%	+586.49%	14.99B
EXELIXIS, INC.	-7.94%	-6.74%	+38.42%	+157.78%	14.25B
Average	+2.18%	+4.25%	+45.89%	+172.18%	24.91B
Weighted average by Cap.	+1.56%	+3.64%	+41.91%	+147.90%

	2023	2024
Net sales	-	278.95 0.2 0.17 0.16 0.15 0.28 18.68 0.28 1.86 0.73 9.33 0.74 0.72 31.07
Net income	-17.88B -12.57M -10.91M -10.21M -9.34M -17.64M -1.2B -17.87M -119M -46.89M -598M -47.19M -46.16M -1.99B	-14.06B -9.88M -8.58M -8.03M -7.35M -13.87M -941M -14.05M -93.94M -36.87M -470M -37.1M -36.3M -1.57B
Net Debt	-45.96B -32.31M -28.04M -26.26M -24.02M -45.35M -3.08B -45.94M -307M -121M -1.54B -121M -119M -5.12B	-37.44B -26.32M -22.84M -21.39M -19.57M -36.94M -2.51B -37.42M -250M -98.2M -1.25B -98.83M -96.68M -4.17B